Abstract
Abstract
Objectives
“True” breast cancers, defined as not being visible on prior screening mammograms, are expected to be more aggressive than “missed” cancers, which are visible in retrospect. However, the evidence to support this hypothesis is limited. We compared the risk of death from any cause for women with true, minimal signs, and missed invasive screen-detected (SDC) and interval breast cancers (IC).
Methods
This nation-wide study included 1022 SDC and 788 IC diagnosed through BreastScreen Norway during 2005–2016. Cancers were classified as true, minimal signs, or missed by five breast radiologists in a consensus-based informed review of prior screening and diagnostic images. We used multivariable Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of death from any cause associated with true, minimal signs, and missed breast cancers, adjusting for age at diagnosis, histopathologic tumour diameter and grade, and subtype. Separate models were created for SDC and IC.
Results
Among SDC, 463 (44%) were classified as true and 242 (23%) as missed; among IC, 325 (39%) were classified as true and 235 (32%) missed. Missed SDC were associated with a similar risk of death as true SDC (HR = 1.20, 95% CI (0.49, 2.46)). Similar results were observed for missed versus true IC (HR = 1.31, 95% CI (0.77, 2.23)).
Conclusions
We did not observe a statistical difference in the risk of death for women diagnosed with true or missed SDC or IC; however, the number of cases reviewed and follow-up time limited the precision of our estimates.
Key Points
• An informed radiological review classified screen-detected and interval cancers as true, minimal signs, or missed based on prior screening and diagnostic mammograms.
• It has been hypothesised that true cancers, not visible on the prior screening examination, may be more aggressive than missed cancers.
• We did not observe a statistical difference in the risk of death from any cause for women with missed versus true screen-detected or interval breast cancers.
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine
Reference40 articles.
1. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Office for Official Publications of the European Communities, Luxembourg
2. Lauby-Secretan B, Scoccianti C, Loomis D et al (2015) Breast-cancer screening--viewpoint of the IARC Working Group. N Engl J Med 372:2353–2358
3. Solbjør M, Forsmo S, Skolbekken JA, Siersma V, Brodersen J (2018) Psychosocial consequences among women with false-positive results after mammography screening in Norway. Scand J Prim Health Care 36:380–389
4. Long H, Brooks JM, Harvie M, Maxwell A, French DP (2019) How do women experience a false-positive test result from breast screening? A systematic review and thematic synthesis of qualitative studies. Br J Cancer 121:351–358
5. Salz T, Richman AR, Brewer NT (2010) Meta-analyses of the effect of false-positive mammograms on generic and specific psychosocial outcomes. Psychooncology 19:1026–1034
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献